UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	ROVAL
OMB Number:	3235-0287
Estimated average I	burden
houre par roepanea	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	I. Name and Address of Reporting Person * Alleva Lawrence M				2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
	APTIMMU	(First) UNE THERAPEU LTON PARK	(Middle) JTICS PLC,, 60	3. Date 07/01/			nsact	ion (Month/Day	//Year)		Officer (give ti	itle below)		specify below	2)
(Street) ABINGDON, X0 OX14 4RX			4. If An	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _Form filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqu					Acquired,	ired, Disposed of, or Beneficially Owned					
1.Title of So (Instr. 3)	1.Title of Security 2. Transaction Date (Month/Day/Yea		Execution Date, if any (Month/Day/Year)				(A) or		(D) Owner Trans	Owned Following Reported Transaction(s) (Instr. 3 and 4)		C F C o	orm: birect (D) r Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									rm are not rec		espond ur	less the f		•	
			Table I					in this fo a current quired, Dispose	rm are not red	control nu	espond ur ımber.	less the f		;	, ,
Security	2. Conversion or Exercise Price of Derivative Security	*****	3A. Deemed Execution Date, if	4. Transact Code	tion	5. Number Derivative Securities Acquired (or Dispose (D)	r of (A) ed of	in this fo a current quired, Dispose s, options, conv 6. Date Exerci Expiration Da (Month/Day/Y	rm are not rectly valid OMB ed of, or Benefit vertible securities isable and te	control nu	espond ur imber. ed I Amount ing	8. Price of	9. Number of Derivative Securities Beneficially Owned Following	10. Owners Form of Derivati Security Direct (1	Ownersh (Instr. 4)
1. Title of Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transact Code	tion	5. Number Derivative Securities Acquired (or Dispose	r of (A) ed of	in this fo a current quired, Dispose s, options, conv 6. Date Exerci Expiration Da (Month/Day/Y	rm are not rectly valid OMB ed of, or Benefit vertible securities isable and te	control nucleis) 7. Title and of Underlyis Securities	espond ur imber. ed I Amount ing	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	10. Owners! Form of Derivati Security Direct (I or Indire	of Indire Benefici Ownersh (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transact Code	tion	5. Number Derivative Securities Acquired (or Dispose (D) (Instr. 3, 4	r of (A) ed of	in this fo a current quired, Dispose s, options, conv 6. Date Exerci Expiration Da (Month/Day/V	rm are not rectly valid OMB ed of, or Benefit vertible securities isable and te	control nucleis) 7. Title and of Underlyis Securities	espond ur imber. ed I Amount ing	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Owners! Form of Derivati Security Direct (lor Indirect)	of Indire Benefici Ownersh (Instr. 4)

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Alleva Lawrence M C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK ABINGDON, X0 OX14 4RX	X				

Signatures

/s/ Lawrence Michael Alleva	07/01/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise price was converted from GBP0.23 based on an exchange rate of \$U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.